Myelodysplastic Syndromes (MDS)

Sweet Syndrome and MDS

Thumbnail for video Watch Now

Topic(s)
Myelodysplastic Syndromes (MDS)
Related Bone Marrow Failure Diseases and Malignancies
Presenter(s)
Aditi Shastri, M.B.B.S.
Dr. Aditi Shastri, M.B.B.S. is a Hematologist/Oncologist at Montefiore Medical Center and is an Assistant Professor at the Albert Einstein College of Medicine. Dr. Shastri earned her medical degree from Lokmanya Tilak Municipal Medical College and is an experienced clinical…

Short Telomere Syndrome: Implications for MDS and AML Patients

Thumbnail for video Watch Now

Topic(s)
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Related Bone Marrow Failure Diseases and Malignancies
Presenter(s)
Mary Armanios, MD
Short telomere syndrome is a genetic mutation that has significant implications for MDS and AML patients. This webinar provides an overview of the subject and will address the specific impact for bone marrow failure disease patients. Our speaker, Mary Armanios, M.D., is the…

A Caregiver's Story: MDS Diagnosis Changes their Lives

I know my fiancé well.  Even though he seemed to be healthy and his job kept him active, I knew it had been a long time since he had a medical physical, so I pushed him into an appointment.

Without symptoms, the doctor suggested routine blood work as a part of the physical.  We were surprised that all his counts were low.  The doctor decided to check again in a month, so I made sure that his diet was healthier and that he took vitamins, hoping that would correct any problem.  

Is blood transfusion safe during the COVID-19 pandemic?

The rapid spread of the coronavirus disease 2019 (COVID-19) pandemic has challenged healthcare systems to re-organize the management of patients in a short period. The causative pathogen of this pandemic is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), one of seven coronaviruses that can be found in humans. It is a rapidly mutating, enveloped, ssRNA, beta-coronavirus. The initial reports published after the pandemic spread showed a transmissibility rate of 2.2 and possibly low values of dispersion.

Overcoming Clinical Challenges Associated With TP53-Mutant MDS, AML

Original Publication Date
Article Source
External Web Content
TP53-mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival. Across TP53-altered MDS and AML…

Martha L. Arellano, MD

Institution
Emory University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
About
Martha L. Arellano, MD, is an Associate Professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine where she serves as Associate Director of the Division of Hematology. Board certified in hematology, medical oncology and internal medicine, Dr. Arellano specializes in the treatment of leukemia and myelodysplastic syndromes. She started practicing with Emory Healthcare in 2006. Dr. Arellano is a clinical member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University. She currently leads the

Guadecitabine Maintenance Therapy Shows Promise in High Risk MDS/AML Patients

Original Publication Date
Article Source
External Web Content
Guadecitabine (SGI-110), when given as maintenance therapy following allogeneic stem cell transplantation (allo-SCT), showed promising relapse-free survival rates (RFS) with manageable safety in high-risk patients with myelodysplastic syndromes/acute myeloid leukemia (MDS/AML)…

GTB-3550 TriKE Stimulates Natural Killer Cell Function in MDS and AML

Original Publication Date
Article Source
External Web Content
December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia. GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk…
Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.